Nazar Z, Al Hail M, Al-Shaibi S, Hussain T, Abdelkader N, Pallivalapila A
Int J Clin Pharm. 2023; 45(6):1424-1433.
PMID: 37454024
PMC: 10682051.
DOI: 10.1007/s11096-023-01616-7.
Matlala M, Gous A, Meyer J, Godman B
Front Pharmacol. 2020; 11:1267.
PMID: 32973508
PMC: 7466677.
DOI: 10.3389/fphar.2020.01267.
Parrish 2nd R
Pharmacy (Basel). 2018; 6(3).
PMID: 30041407
PMC: 6165227.
DOI: 10.3390/pharmacy6030072.
Parrish 2nd R
Pharmacy (Basel). 2018; 6(3).
PMID: 30036933
PMC: 6163517.
DOI: 10.3390/pharmacy6030069.
Munshi K, Mager D, Ward K, Mischel B, Henderson R
J Manag Care Spec Pharm. 2018; 24(2):124-131.
PMID: 29384030
PMC: 10397757.
DOI: 10.18553/jmcp.2018.24.2.124.
Variation in Formulary Management Practices Within the Department of Veterans Affairs Health Care System.
Radomski T, Good C, Thorpe C, Zhao X, Marcum Z, Glassman P
J Manag Care Spec Pharm. 2016; 22(2):114-20.
PMID: 27015250
PMC: 7024562.
DOI: 10.18553/jmcp.2016.14251.
A prescription for improving drug formulary decision making.
Schiff G, Galanter W, Duhig J, Koronkowski M, Lodolce A, Pontikes P
PLoS Med. 2012; 9(5):1-7.
PMID: 22629233
PMC: 3358338.
DOI: 10.1371/journal.pmed.1001220.
The Truth about Hospital Formularies, Part 1: We've Come a Long Way-or Have We?.
Grissinger M
P T. 2009; 33(8):441.
PMID: 19750172
PMC: 2730104.
The Truth about Hospital Formularies, Part 2: Survey Shows Many Myths Still Exist Years Later.
Grissinger M
P T. 2009; 33(9):504-10.
PMID: 19750028
PMC: 2730123.
Pharmacy utilization and the Medicare Modernization Act.
Maio V, Pizzi L, Roumm A, Clarke J, Goldfarb N, Nash D
Milbank Q. 2005; 83(1):101-30.
PMID: 15787955
PMC: 2690380.
DOI: 10.1111/j.0887-378X.2005.00337.x.
The need for an iterative process for assessing economic outcomes associated with SSRIs.
Skaer T, Sclar D, Robison L, Galin R
Pharmacoeconomics. 2001; 18(3):205-14.
PMID: 11147388
DOI: 10.2165/00019053-200018030-00001.
Rational pharmacotherapy in The Netherlands: formulary management in Dutch hospitals.
Fijn R, de Jong-van den Berg L, Brouwers J
Pharm World Sci. 1999; 21(2):74-9.
PMID: 10380234
DOI: 10.1023/a:1008654609916.
The effect of managed care on prescription drug costs and benefits.
Lyles A, Palumbo F
Pharmacoeconomics. 1999; 15(2):129-40.
PMID: 10351187
DOI: 10.2165/00019053-199915020-00002.
Using feedback letters to influence the use of antiulcer agents in a Medicaid program.
Raisch D, Sleath B
J Gen Intern Med. 1999; 14(3):145-50.
PMID: 10203619
PMC: 1496557.
DOI: 10.1046/j.1525-1497.1999.00305.x.
Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 1: Depression and its treatment.
Henry J, Rivas C
Pharmacoeconomics. 1997; 11(5):419-43.
PMID: 10168031
DOI: 10.2165/00019053-199711050-00005.
Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.
Guze B
Pharmacoeconomics. 1996; 9(5):430-42.
PMID: 10160255
DOI: 10.2165/00019053-199609050-00006.
Economic incentives and disincentives for efficient prescribing.
Rittenhouse B
Pharmacoeconomics. 1994; 6(3):222-32.
PMID: 10155265
DOI: 10.2165/00019053-199406030-00006.
US Medicaid drug formularies: do they work?.
Moore W, Newman R
Pharmacoeconomics. 1991; 1(Suppl 1):28-31.
PMID: 10146928
DOI: 10.2165/00019053-199200011-00008.
Drug utilisation review and pharmacoeconomics: interaction after parallel development?.
Garattini S, Tognoni G
Pharmacoeconomics. 1993; 4(3):162-72.
PMID: 10146920
DOI: 10.2165/00019053-199304030-00002.
The formulary decision-making process in a health maintenance organisation setting.
Shepherd M, Salzman R
Pharmacoeconomics. 1993; 5(1):29-38.
PMID: 10146864
DOI: 10.2165/00019053-199405010-00005.